Guardant Health is a leading molecular diagnostics company focused on enabling precision medicine through use of its proprietary blood-based assays, focused in the emerging liquid biopsy arena. The Company’s core Health Oncology Platform is designed to improve patient clinical outcomes, lower healthcare costs, and accelerate biopharmaceutical drug development to manage cancer across all stages of the disease. The Company’s platform is designed to address a major challenge in oncology: the limitations and time / cost intensity inherent to a tissue-based diagnostic approach. Since the Company’s inception in 2013, Guardant has launched several liquid biopsy-based test products, enabled by a routine blood draw, aimed at both clinical and biopharma end-customer markets. The Company’s two commercial products are Guardant360 (launched 2014) and GuardantOMNI, for advanced-stage cancer patients. Guardant360 is a 73 gene assay that supports treatment selection in advanced solid tumor cancers, while GuardantOMNI represents a more comprehensive offering with comparable analytical performance. The test was developed in collaboration with several leading biopharma companies including Merck MSD, Merck KGaA, Pfizer, AstraZeneca and Bristol-Myers Squibb